Clinical Trial News

Luis Rios, diagnosed with stage IV pancreatic cancer in 2017, credits his recovery to PanCAN's Know Your Tumor program, which identified a rare RAD51C mutation. After chemotherapy and a clinical trial, he tried immunotherapy, leading to a dramatic improvement. Now, Dr. Peter Hosein uses Luis' case to research broader immunotherapy applications for pancreatic cancer patients.

Clinical trials at the Miller School of Medicine and 14 other sites are testing hyperbaric oxygen therapy (HBOT) for ulcerative colitis. HBOT, which increases oxygen delivery to tissues, has shown potential in reducing inflammation and improving outcomes in previous small trials. The study aims to determine if HBOT, used adjunctively with medications, can reduce the need for surgery and improve inflammation in ulcerative colitis patients.

Summit Therapeutics' experimental drug outperformed Merck's Keytruda in non-small cell lung cancer, led by iconoclastic figure Bob Duggan, a billionaire with no drug industry experience.

Corvus Pharmaceuticals initiates a Phase 3 trial of soquelitinib for relapsed/refractory peripheral T-cell lymphoma (PTCL), a disease with no fully approved treatments. Soquelitinib, an ITK inhibitor, aims to offer a safer and more effective alternative to standard chemotherapy.

Lexicon Pharmaceuticals announced positive sotagliflozin clinical trial results for type 2 diabetes, improving time-in-range (TIR) and glucose variability. The data, presented at the 60th EASD Annual Meeting, showed sotagliflozin 400 mg and 200 mg doses approaching the ADA TIR target of 70%.

Boehringer Ingelheim reported positive outcomes from the Beamion LUNG-1 trial, assessing zongertinib for treating NSCLC with HER2 mutations. The trial met its primary endpoint, showing a 66.7% objective response rate and a tolerable safety profile, with no treatment-related deaths.

NPC patients were treated based on stage, with radiotherapy alone for stages I–II, and concurrent chemoradiotherapy (CCRT) for stages II–IVA, combined with adjuvant or induction chemotherapy. Follow-ups included MRI at varying intervals, with progression-free survival (PFS) as the primary endpoint. MRI protocols used a 1.5-Tesla scanner with specific T1WI, T2WI, and CET1-w settings. Radiomics signature construction involved preprocessing, segmentation by radiologists, feature extraction, and selection using mRMR and LASSO methods. Pathomics signature used a Swin Transformer to extract features from H&E-stained slides. A radiopathomics model was built integrating radiomics, pathomics signatures, and clinical factors, evaluated by C-index and calibration curve.

NHS approves groundbreaking myeloma drugs elranatamab and teclistamab for patients who have received three or more treatments. These bispecific antibodies, the first new class of myeloma drugs in nearly seven years in Scotland, can halt the disease for at least 11 months and induce complete remission in some previously non-responders.

A European epilepsy drug, sulthiame, shows potential as a treatment for sleep apnea, reducing breathing pauses and increasing blood oxygen levels in a clinical trial. Sulthiame, not approved in the U.S., targets the respiratory system by inhibiting carbonic anhydrase, stimulating upper airway muscles. Further trials are needed to confirm its benefits and long-term effects.

Dr. David J. Bearss, CEO of Halia Therapeutics, will present Phase II study results on HT-6184's efficacy in reducing post-procedural inflammation and pain at the 6th Inflammasome Therapeutics Summit on September 12, 2024, in Boston.